Changes in Beneficial Ownership · 4
Neuropace, Inc.
NPCENASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1780693812.xml
Filing details
- Report period
- 2026-06-05
- Issuer
- NeuroPace Inc
- Issuer CIK
- 0001528287
- Trading symbol
- NPCE
Reporting owner 1
- Name
- Kumar Rakhi
- Reporting owner CIK
- 0001856296
- Relationship
- Director
- Address
- C/O NEUROPACE, INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-06-05 | A · Form 4 | 2,890[F1] | A | 0 | 22,050 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 15.74 | 2026-06-05 | A · Form 4 | 5,368 | A | 0 | [F2] | 2036-06-04 | Common Stock | 5,368 | 5,368 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date.↩ 1
- F2
- The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date.↩ 1
Signature 1
- Signed
- /s/ Leah Akin, Attorney-in-Fact
- Date
- 2026-06-05
Company context
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.